Spahn J D, Landwehr L P, Nimmagadda S, Surs W, Leung D Y, Szefler S J
Department of Pediatrics, National Jewish Center for Immunology and Respiratory Medicine, Denver, CO 80206, USA.
J Allergy Clin Immunol. 1996 Dec;98(6 Pt 1):1073-9. doi: 10.1016/s0091-6749(96)80194-1.
Glucocorticoids are important medications used to control the airway inflammation associated with asthma. Synthetic glucocorticoids vary in their binding affinity for the glucocorticoid receptor (GCR).
We compared hydrocortisone, beclomethasone dipropionate, triamcinolone acetonide, flunisolide, and budesonide with regard to their capacity to inhibit phytohemagglutinin-induced peripheral blood mononuclear cell proliferation from six patients with steroid-sensitive asthma and seven patients with steroid-resistant asthma. Peripheral blood mononuclear cell GCR binding affinities for dexamethasone and budesonide were also determined for both patient groups by using a radioligand binding assay and Scatchard analysis.
Dose-dependent inhibition was demonstrated for all glucocorticoids in both patient groups, with the steroid-resistant group requiring approximately 2 log-fold more glucocorticoids for an equivalent degree of inhibition. The mean concentrations necessary to cause 50% inhibition of lymphocyte proliferation (IC50s) for the steroid-sensitive group ranged from 2 x 10(-10) mol/L for budesonide to 7 x 10(-8) mol/L for hydrocortisone, whereas the mean IC50s for the steroid-resistant group ranged from approximately 2 x 10(-8) mol/L for budesonide to greater than 10(-6) mol/L for hydrocortisone. In addition, a significant correlation was noted between the degree of inhibition of lymphocyte proliferation (IC50) and the binding affinity of dexamethasone to the GCR. Patients with steroid-resistant asthma have been shown to have a reduced GCR binding affinity. The GCR binding affinity for budesonide was significantly higher in both groups (i.e., lower dissociation constant) than that obtained for dexamethasone.
These data suggest that glucocorticoids such as budesonide, by virtue of their high GCR binding affinities and greater ability to suppress lymphocyte proliferation, may therefore be beneficial in the management of difficult-to-control asthma.
糖皮质激素是用于控制与哮喘相关的气道炎症的重要药物。合成糖皮质激素对糖皮质激素受体(GCR)的结合亲和力各不相同。
我们比较了氢化可的松、二丙酸倍氯米松、曲安奈德、氟尼缩松和布地奈德抑制来自6例激素敏感型哮喘患者和7例激素抵抗型哮喘患者的植物血凝素诱导的外周血单个核细胞增殖的能力。还通过放射性配体结合试验和Scatchard分析测定了两组患者外周血单个核细胞对地塞米松和布地奈德的GCR结合亲和力。
两组患者中所有糖皮质激素均表现出剂量依赖性抑制,激素抵抗组达到同等抑制程度所需的糖皮质激素大约多2个对数级。激素敏感组导致淋巴细胞增殖50%抑制(IC50)所需的平均浓度范围为布地奈德2×10⁻¹⁰ mol/L至氢化可的松7×10⁻⁸ mol/L,而激素抵抗组的平均IC50范围为布地奈德约2×10⁻⁸ mol/L至氢化可的松大于10⁻⁶ mol/L。此外,观察到淋巴细胞增殖抑制程度(IC50)与地塞米松对GCR的结合亲和力之间存在显著相关性。已证明激素抵抗型哮喘患者的GCR结合亲和力降低。两组中布地奈德的GCR结合亲和力均显著高于地塞米松(即解离常数更低)。
这些数据表明,布地奈德等糖皮质激素由于其高GCR结合亲和力和更强的抑制淋巴细胞增殖能力而可能有助于治疗难治性哮喘。